-
Clinical performance of non-invasive prenatal testing (NIPT) using targeted cell-free DNA analysis in maternal plasma with microarrays or next generation sequencing (NGS) is consistent across multiple controlled clinical studies.
Stokowski R, Wang E, White K, Batey A, Jacobsson B, Brar H, Balanarasimha M, Hollemon D, Sparks A, Nicolaides K, Musci TJ.
Prenat Diagn 2015;35:1243-6. pdf -
First-trimester contingent screening for trisomies 21, 18 and 13 by fetal nuchal translucency and ductus venosus flow and maternal blood cell-free DNA testing.
Kagan KO, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2015;45:42-7. pdf -
First-trimester screening for trisomy 21 using nuchal translucency and nasal bone evaluations in a selected and an unselected population.
Sonek J, Cicero S, Nicolaides K.
Am J Obstet Gynecol 2007;196:19. -
Some thoughts on the true value of ultrasound.
Nicolaides KH.
Ultrasound Obstet Gynecol 2007;30:671-4. -
Discordance in nuchal translucency thickness in the prediction of severe twin-to-twin transfusion syndrome.
Kagan KO, Gazzoni A, Sepulveda-Gonzalez G, Sotiriadis A, Nicolaides KH.
Ultrasound Obstet Gynecol 2007;29:527-32. -
Nuchal translucency and the risk of congenital heart disease.
Hyett J, Sonek J, Nicolaides KH.
Obstet Gynecol 2007;109:1455-6. -
Nuchal translucency measurements for first-trimester screening: The 'price' of inaccuracy.
Evans MI, Van Decruyes H, Nicolaides KH.
Fetal Diagn Ther 2007;22:401-404.